NASDAQ:CYTKCytokinetics Stock Price, Forecast & News

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CYTK stock has increased by 71.9% and is now trading at $20.68. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cytokinetics.

Cytokinetics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Cytokinetics.

Cytokinetics, Inc. (NASDAQ:CYTK) released its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.50) by $0.16. The biopharmaceutical company had revenue of $3.83 million for the quarter, compared to analysts' expectations of $4.92 million. Cytokinetics had a negative net margin of 592.61% and a negative return on equity of 10,351.99%. View Cytokinetics' earnings history.

Cytokinetics issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, March, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $18-22 million, compared to the consensus revenue estimate of $28.03 million.

7 brokerages have issued 1-year price targets for Cytokinetics' shares. Their forecasts range from $20.00 to $35.00. On average, they expect Cytokinetics' share price to reach $26.43 in the next twelve months. This suggests a possible upside of 27.8% from the stock's current price. View analysts' price targets for Cytokinetics.

News headlines about CYTK stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cytokinetics earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutCytokinetics.

Cytokinetics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 7,800,000 shares, a drop of 8.6% from the April 30th total of 8,530,000 shares. Based on an average trading volume of 1,010,000 shares, the short-interest ratio is presently 7.7 days. Currently, 14.4% of the shares of the stock are short sold. View Cytokinetics' Current Options Chain.

Some companies that are related to Cytokinetics include Myokardia (MYOK), Forty Seven (FTSV), Emergent Biosolutions (EBS), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), PPD (SDGR), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR), GW Pharmaceuticals PLC- (GWPH), Zai Lab (ZLAB), Evotec (EVTCY), Allakos (ALLK), ChemoCentryx (CCXI) and Agios Pharmaceuticals (AGIO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (AMGN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Geron (GERN), TherapeuticsMD (TXMD), Gilead Sciences (GILD) and Immunomedics (IMMU).

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Cytokinetics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.35%), Wasatch Advisors Inc. (5.05%), State Street Corp (4.52%), Foresite Capital Management IV LLC (3.66%), Two Sigma Advisers LP (1.13%) and Bank of New York Mellon Corp (1.04%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Fady Ibraham Malik, Robert I Blum, Santo J Costa, Value Fund L P Biotechnology and Wendall Wierenga. View institutional ownership trends for Cytokinetics.

CYTK stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Foresite Capital Management IV LLC, Federated Hermes Inc., Two Sigma Investments LP, Pinnacle Associates Ltd., UBS Group AG, Arizona State Retirement System, and Bank of New York Mellon Corp. Company insiders that have sold Cytokinetics company stock in the last year include Bvf Partners L P/Il, Fady Ibraham Malik, Robert I Blum, Santo J Costa, and Wendall Wierenga. View insider buying and selling activity for Cytokinetics.

CYTK stock was purchased by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Burrage Capital Management LLC, Atom Investors LP, JPMorgan Chase & Co., BNP Paribas Arbitrage SA, Two Sigma Advisers LP, State Street Corp, and Assenagon Asset Management S.A.. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology. View insider buying and selling activity for Cytokinetics.

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CYTK stock can currently be purchased for approximately $20.68.

Cytokinetics has a market capitalization of $1.23 billion and generates $26.87 million in revenue each year. The biopharmaceutical company earns $-121,690,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Cytokinetics employs 130 workers across the globe.

The official website for Cytokinetics is www.cytokinetics.com.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]